ALDA Receives US Patent For T36

ALDA has received US Patent Number 7560422 from US Patent and Trademark Office (USPTO). The patent is a continuation of US Patent Number 7338927 that was issued on March 4, 2008 and provides further protection for ALDA’s T36 formulation until August 20, 2022.

The new patent includes claims to additional aspects of the T36 formulation, including the use of T36 as a component of a personal lubricant. It is to prevent or reduce the transmission of sexually transmitted diseases including herpes, chlamydia and HIV, and for use in sanitizers and cleansers in creams, ointments and wipes.

Terrance Owen, president and CEO of ALDA, said: Issuance of this new US patent is an important step for ALDA because it provides protection for T36 for certain therapeutic uses. This ties in well with our strategy of registering T36 for therapeutic applications and provides a complement to the new PCT application which is in progress and covers more broad ranging therapeutic applications.”